Navigation Links
CT Imaging With Novel Contrast Agent May Predict Heart Attack in Waiting

A new imaging technology may hold the key to not only stopping heart attacks in their tracks but also preventing them for ever occurring//. Researchers at Mount Sinai School of Medicine have shown the use computed tomography (CT) imaging along with a novel contrast agent know as N1177 can detect dangerous, high-risk plaque which cause heart attack and stroke. The findings may help physicians diagnosis a heart attack before the attack occurs.

High-risk plaque is characterized by their cellular and biologic structure. High-risk plaque rich in macrophages or cells can rupture, eventually causing a heart attack or stroke. Early identification of high-risk plaque in coronary arteries may be useful to prevent cardiac events but one major hurdle in detecting high-risk plaque is the lack of an imaging modality that allows physicians to see the composition of dangerous plaque, explains study author Zahi A. Fayad, PhD, FAHA, FACC, Professor of Radiology and Medicine (Cardiology) and director of the Translational and Molecular Imaging Institute at Mount Sinai School of Medicine. “Coronary CT imaging has advanced the diagnosis and prognosis of heart disease,” says Dr. Fayad. “But, what if we had the opportunity to prevent a heart attack from happening? This modality may allow us to do just that.”

A team of researchers led by Dr. Fayad tested an iodinated nanoparticulate contrast agent called N1177 for the detection of macrophages in an animal model with 64-slice CT. High-risk plaque in this animal model contained high levels of macrophages which are similar in size and content to human coronary plaques. Researchers compared the enhancement of macrophage rich plaque after the injection of N1177 and a conventional CT contrast agent. The enhancement of the macrophage rich plaque after the injection of N1177 was significantly higher and specific inside of the vessel wall than after injecting the conventional CT contrast agent.

“We were amazed a t these results. The introduction of N1177 allows us for the first time to look directly at the coronary arteries and pinpoint these dangerous, heart attack causing plaque,” said Dr. Fayad.

“N1177 had successfully progressed through Phase 1 clinical trials for use as a cancer staging agent,” said Don Skerrett, chief executive officer of NanoScan Imaging, LLC, and provider of N1177. “The unique properties of N1177 make it a versatile agent with a range of applications including: intravenous administration for the assessment of atherosclerosis and identification of vulnerable plaque, inhalation delivery for improved lung cancer staging and subcutaneous delivery for assessing cancerous extension into lymph nodes.”

The Mount Sinai researchers also believe this development may have broader clinical implication.

“N1177-enhanced CT will be helpful for diagnosis and prognosis of disease states. In the future, this technology may allow for the targeting of macrophages to specifically dispense therapeutic agents to disease tissue.”

Source-Newsise
SRM
'"/>




Related medicine news :

1. Imaging Modality That Might Help Diagnose Depression
2. Being Obese Increases Ones Risk Of A wrong Diagnosis During Medical Imaging
3. Optical Imaging Added To Ultrasound To Improve Imaging Of Breast Cancer
4. Using Eyes As The Line Of Reference For Fetal Brain Imaging
5. Three In One Ultrasound Probe For 3-D Imaging Of Heart And Tissue Destruction Developed
6. New Computerized Imaging Systems Help In Better Dental Treatment Planning
7. Magnetic Resonance Imaging Can Now Be Used For Mind Reading
8. New Cardiac Angiography Technique For Improved Imaging Of Coronary Veins
9. Brain Is More Active While Hiding The Truth, Reveals fMRI Imaging
10. 3-D Imaging For Monitoring Reactor Systems, Power Plants
11. Brian Imaging Can Foretell Results Of Treating Depression
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will demonstrate its ... Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention Center in ... the gold standard for high-definition, in-ear earphones. This classic earphone has been updated ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting ... Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted ... providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from New York’s ... care practitioners on the latest breakthroughs in the prevention, diagnosis and treatment of ... according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of SightMD ...
(Date:1/17/2017)... ... ... Neil H. Greco Insurance Agency, a northern New Jersey firm that provides ... a charity drive to raise awareness of heart disease and promote habits that improve ... is responsible for 1 in every 4 deaths at the national level each year. ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley healthcare ... blind clinical study for its dental gel that shows significant reduction in plaque levels ... containing triclosan. The study was conducted at the Beckman Laser Institute at UC Irvine ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... -- OrthoAccel ® Technologies, Inc. announces that the ... Effect of Vibration on Molar Distalization," a study that ... Jay Bowman , this prospective, peer-reviewed clinical study concluded ... ® speeds up molar distalization rates in the ... days to move the upper molars into a normal, ...
(Date:1/17/2017)... 2017   Tocagen Inc ., a clinical-stage, cancer-selective gene therapy ... president, research and pharmaceutical development at Tocagen, will present at ... Jan. 17-20 in Miami . ... ... for replicating viruses - what to do when and why Date ...
(Date:1/17/2017)... Jan. 17, 2017  EMD Serono, the biopharmaceutical business ... in the U.S. and Canada , ... joined the company as Senior Vice President and Head ... Smith will oversee the Fertility and Endocrinology businesses in ... launched its first product last year with Gidget™, a ...
Breaking Medicine Technology: